A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial

A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcription (JAK-STAT) pathway. Moreover, it reduces the receptor mediated vi...

Full description

Bibliographic Details
Main Authors: G. Moreno-González, A. Mussetti, A. Albasanz-Puig, I. Salvador, A. Sureda, C. Gudiol, R. Salazar, M. Marin, M. Garcia, V. Navarro, I. de la Haba Vaca, E. Coma, G. Sanz-Linares, X. Dura, S. Fontanals, G. Serrano, C. Cruz, R. Mañez
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Trials
Subjects:
COVID19
randomised controlled trial
baricitinib
jak inhibitors
respiratory insufficiency
oncological patients
Online Access:https://doi.org/10.1186/s13063-021-05072-4

Internet

https://doi.org/10.1186/s13063-021-05072-4

Similar Items